Gestational Diabetes Act of 2010 or the GEDI Act - Amends the Public Health Service Act to direct the Secretary of Health and Human Services (HHS), acting through the Director of the Centers for Disease Control and Prevention (CDC), to develop a multisite gestational diabetes research project within the diabetes program of the CDC to expand and enhance surveillance data and public health research on gestational diabetes. Requires such research project to address: (1) procedures to establish accurate and efficient systems for the collection of gestational diabetes data; (2) the progress of collaborative activities with the National Vital Statistics System, the National Center for Health Statistics, and state health departments to improve surveillance of gestational diabetes; (3) postpartum methods of tracking women with gestational diabetes after delivery and targeted interventions to lower the incidence of type 2 diabetes in such women; (4) variations in the distribution of diagnosed and undiagnosed gestational diabetes; and (5) factors and culturally sensitive interventions that influence risks and reduce the incidence of gestational diabetes and related complications during childbirth. Requires the Secretary, not later than two years after the enactment of this Act, to report on the findings and recommendations of the research project.
Requires the Secretary to expand and intensify public health research on gestational diabetes, including; (1) developing and testing novel approaches for improving postpartum testing or screening and for preventing type 2 diabetes in women with a history of gestational diabetes; and (2) conducting research to further understanding of the factors and health systems that influence the risk of gestational diabetes and the development of type 2 diabetes in women with a history of gestational diabetes.
Requires the Secretary, acting through the Director of the CDC, to: (1) award grants on a competitive basis for demonstration projects that implement evidence-based interventions to reduce the incidence of gestational diabetes, the recurrence of such disease in subsequent pregnancies, and the development of type 2 diabetes in women with a history of gestational diabetes; and (2) report to Congress, not later than four years after the enactment of this Act, on the results of the demonstration projects. Sets forth priorities for awarding grants and requirements for the use of grant funds for carrying out demonstration projects.
Requires the Secretary, acting through the Director of the CDC, to work with state and Indian tribal-based diabetes prevention and control programs assisted by the CDC to encourage postpartum follow-up after gestational diabetes to reduce the incidence of gestational diabetes and its recurrence, the development of type 2 diabetes in at-risk women, and related complications.
Authorizes appropriations for FY2012-FY2016.
[Congressional Bills 111th Congress]
[From the U.S. Government Publishing Office]
[H.R. 5354 Introduced in House (IH)]
111th CONGRESS
2d Session
H. R. 5354
To establish an Advisory Committee on Gestational Diabetes, to provide
grants to better understand and reduce gestational diabetes, and for
other purposes.
_______________________________________________________________________
IN THE HOUSE OF REPRESENTATIVES
May 20, 2010
Mr. Engel (for himself, Mr. Burgess, Ms. DeGette, Mr. Castle, Mr. Gene
Green of Texas, Mr. King of New York, Mrs. Capps, Mr. Gonzalez, Ms.
Baldwin, Mr. Rangel, Mr. Higgins, Mrs. Maloney, Mr. Ackerman, Ms.
Clarke, Ms. Lee of California, Mr. Serrano, and Mr. Doyle) introduced
the following bill; which was referred to the Committee on Energy and
Commerce
_______________________________________________________________________
A BILL
To establish an Advisory Committee on Gestational Diabetes, to provide
grants to better understand and reduce gestational diabetes, and for
other purposes.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ``Gestational Diabetes Act of 2009''
or the ``GEDI Act''.
SEC. 2. FINDINGS.
The Congress finds the following:
(1) The prevalence of gestational diabetes among pregnant
women in the United States is increasing.
(2) Gestational diabetes, which is similar to chronic forms
of diabetes, normally appears at 24 to 28 weeks gestation and
occurs in approximately 4 to 8 percent of pregnant women.
(3) The associated risk factors for gestational diabetes
include overweight, obesity, lack of physical activity,
genetics, ethnicity, and age.
(4) There is disagreement among physicians about how to
treat gestational diabetes, as well as the effectiveness of
current treatment regimens.
(5) Gestational diabetes, which increases the risk of
preeclampsia, also increases a pregnant woman's risk for
developing gestational diabetes in subsequent pregnancies.
(6) Infants of women who develop gestational diabetes may
have extreme increases in birth weight and the risks related to
difficulties during the birthing process, and infants born to
these women--
(A) may subsequently have low blood sugar or
jaundice during the newborn period;
(B) are at increased risk for birth trauma; and
(C) may be at increased risk of developing type 2
diabetes and obesity as an adolescent or adult.
(7) Improved nutrition and increased physical activity
before, during, and after pregnancy may significantly decrease
the rates of gestational diabetes and its recurrence.
(8) Obese pregnant women have a three-fold risk for the
development of gestational diabetes as compared with normal
weight women.
SEC. 3. GESTATIONAL DIABETES.
The Public Health Service Act (42 U.S.C. 201 et seq.) is amended by
adding at the end the following:
``TITLE XXXIII--GESTATIONAL DIABETES
``SEC. 3301. UNDERSTANDING AND MONITORING GESTATIONAL DIABETES DURING
PREGNANCY.
``(a) In General.--The Secretary of Health and Human Services,
acting through the Director of the Centers for Disease Control and
Prevention, shall convene a Research Advisory Committee.
``(b) Membership.--The members of the Research Advisory Committee--
``(1) shall include--
``(A) a representative from the Agency for
Healthcare Research and Quality;
``(B) a representative from the Centers for Disease
Control and Prevention;
``(C) a representative from the National Institutes
of Health;
``(D) a representative from the Office of Minority
Health;
``(E) a representative from the Indian Health
Service;
``(F) a representative from the National Center for
Health Statistics; and
``(G) representatives from other appropriate
Federal agencies; and
``(2) may include representatives from other appropriate
organizations.
``(c) Matters To Be Studied.--The Director of the Centers for
Disease Control and Prevention, in consultation with the Research
Advisory Committee, shall develop a multisite, gestational diabetes
research project within the diabetes program of the Centers for Disease
Control and Prevention to expand and enhance surveillance data and
public health research on gestational diabetes. The project shall
address--
``(1) the procedures to establish accurate and efficient
systems for the collection of gestational diabetes data within
each State and commonwealth, territory, or possession of the
United States;
``(2) the progress of collaborative activities with the
National Vital Statistics System, the National Center for
Health Statistics, and State health departments with respect to
the standard birth certificate, in order to improve
surveillance of gestational diabetes;
``(3) postnatal methods of tracking women who had
gestational diabetes after delivery as well as targeted
interventions proven to lower the incidence of type 2 diabetes
in that population;
``(4) variations in the distribution of diagnosed and
undiagnosed diabetes, and of impaired fasting glucose tolerance
and impaired fasting glucose, within and among groups of women;
and
``(5) factors and culturally sensitive interventions that
influence risks and reduce the incidence of gestational
diabetes during pregnancy and complications during childbirth,
including cultural, behavioral, racial, ethnic, geographic,
demographic, socioeconomic, and genetic factors.
``(d) Meetings.--Not later than 1 year after the establishment of
the gestational diabetes research project under subsection (c), and
annually thereafter, the Research Advisory Committee shall meet to
assess the progress of the project and to update the Secretary of
Health and Human Services, if necessary.
``(e) Report.--Not later than 2 years after the date of the
enactment of this title, and annually thereafter, the Director of the
Centers for Disease Control and Prevention shall generate a report on
the prevalence and trends of gestational diabetes and disseminate the
report to the Secretary of Health and Human Services and appropriate
Federal and non-Federal agencies.
``SEC. 3302. DEMONSTRATION GRANTS TO LOWER THE RATE OF GESTATIONAL
DIABETES DURING PREGNANCY.
``(a) In General.--The Secretary of Health and Human Services,
acting through the Director of the Centers for Disease Control and
Prevention, in consultation with the Research Advisory Committee
established under section 3301, shall award grants, on a competitive
basis, to eligible entities for demonstration projects that build
capacity with key stakeholders, build new surveillance systems, and
implement and evaluate evidence-based interventions to reduce the
incidence of gestational diabetes and its recurrence and prevent type 2
diabetes after pregnancy. In making such grants, the Director give
priority to projects focusing on--
``(1) helping women who have 1 or more risk factors for
developing diabetes;
``(2) working with women who have had gestational diabetes
during a previous pregnancy;
``(3) providing postnatal care for women who had
gestational diabetes;
``(4) tracking cases where gestational diabetes led to the
development of type 2 diabetes;
``(5) educating mothers about the increased risk of their
child developing diabetes;
``(6) working to prevent or delay gestational diabetes and
subsequent type 2 diabetes; and
``(7) achieving outcomes designed to assess efficacy and
cost-effectiveness of interventions that can inform decisions
on long-term sustainability, including third-party
reimbursement.
``(b) Application.--An eligible entity desiring to receive a grant
under this section shall submit to the Director of the Centers for
Disease Control and Prevention--
``(1) an application at such time, in such manner, and
containing such information as the Director may require; and
``(2) a plan to--
``(A) lower the rate of gestational diabetes during
pregnancy; or
``(B) develop methods of tracking women who had
gestational diabetes and develop effective
interventions to lower the incidence of the recurrence
of gestational diabetes and the development of type 2
diabetes.
``(c) Uses of Funds.--An entity receiving a grant under this
section shall use the grant funds to carry out demonstration projects
that implement evidence-based interventions to reduce the incidence of
gestational diabetes and its recurrence, which may include--
``(1) expanding community-based health promotion education,
activities, and incentives focused on the prevention of
gestational diabetes and type 2 diabetes after pregnancy;
``(2) aiding State-based diabetes prevention and control
programs to collect, analyze, disseminate, and report
surveillance data on women with, and at risk for, gestational
diabetes and its recurrence and prevention of type 2 diabetes
after pregnancy;
``(3) building capacity with State-based partners to
implement programs and interventions to reduce the occurrence
of gestational diabetes based on surveillance data; and
``(4) training and encouraging health care providers--
``(A) to promote risk assessment, high-quality
care, and self-management for gestational diabetes and
its recurrence; and
``(B) to prevent type 2 diabetes after pregnancy
and its complications in the practice settings of the
health care providers.
``(d) Reports.--
``(1) CDC report.--Not later than 4 years after the date of
the enactment of this title, the Director of the Centers for
Disease Control and Prevention shall prepare and submit a
report to the Secretary of Health and Human Services concerning
the results of the studies conducted through the grants awarded
under this section.
``(2) Secretary report.--Not later than 90 days after
receiving the report described in paragraph (1), the Secretary
shall prepare and submit a report to the Congress concerning
the results and findings of the report.
``(e) Definition of Eligible Entity.--In this section, the term
`eligible entity' means a nonprofit organization (such as a nonprofit
academic center or community health center) or a State or local health
agency.
``(f) Authorization of Appropriations.--There is authorized to be
appropriated to carry out this section $5,000,000 for each fiscal year
2010 through 2014.
``SEC. 3303. RESEARCH EXPANSION OF GESTATIONAL DIABETES DURING
PREGNANCY.
``(a) In General.--The Director of the Centers for Disease Control
and Prevention shall conduct and support public health research
regarding gestational diabetes. Such research shall include--
``(1) developing and testing novel approaches for improving
postpartum diabetes testing or screening and for preventing
type 2 diabetes in women with a history of gestational
diabetes; and
``(2) conducting public health research to further
understanding of the epidemiologic, socioenvironmental,
behavioral, translation, and biomedical factors and health
systems that influence risk of gestational diabetes and
progression to type 2 diabetes.
``(b) Authorization of Appropriations.--There is authorized to be
appropriated to carry out this section $5,000,000 for each fiscal year
2010 through 2014.
``SEC. 3304. SCREENING FOR GESTATIONAL DIABETES.
``The Director of the Centers for Disease Control and Prevention
shall encourage postpartum screenings after gestational diabetes within
the State-based diabetes prevention and control programs assisted by
the Centers for Disease Control and Prevention, for the purpose of
reducing the incidence of gestational diabetes and its recurrence,
progression to type 2 diabetes, and its related complications.''.
<all>
Referred to the House Committee on Energy and Commerce.
Referred to the Subcommittee on Health.
Subcommittee Hearings Held.
Subcommittee Consideration and Mark-up Session Held.
Forwarded by Subcommittee to Full Committee (Amended) by Voice Vote .
Committee Consideration and Mark-up Session Held.
Ordered to be Reported (Amended) by Voice Vote.
Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 111-633.
Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 111-633.
Placed on the Union Calendar, Calendar No. 373.
Mr. Pallone moved to suspend the rules and pass the bill, as amended.
Considered under suspension of the rules. (consideration: CR H7178-7180)
Llama 3.2 · runs locally in your browser
Ask anything about this bill. The AI reads the full text to answer.
Enter to send · Shift+Enter for new line
DEBATE - The House proceeded with forty minutes of debate on H.R. 5354.
At the conclusion of debate, the chair put the question on the motion to suspend the rules. Mr. Burgess objected to the vote on the grounds that a quorum was not present. Further proceedings on the motion were postponed. The point of no quorum was withdrawn.
Considered as unfinished business. (consideration: CR H7379)
Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.(text: CR 9/28/2010 H7178-7179)
On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR 9/28/2010 H7178-7179)
Motion to reconsider laid on the table Agreed to without objection.
The title of the measure was amended. Agreed to without objection.
Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.